12/11
12:29 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $4.00 price target on the stock, down previously from $7.00.
12/11
07:40 am
prld
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies [Yahoo! Finance]
Medium
Report
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies [Yahoo! Finance]
12/11
07:30 am
prld
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
Medium
Report
Prelude Therapeutics Presents Preliminary Results of Phase 1 Dose-escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies
11/27
07:41 am
prld
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit [Yahoo! Finance]
Low
Report
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit [Yahoo! Finance]
11/27
07:30 am
prld
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
Low
Report
Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit
11/11
11:49 am
prld
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) [Yahoo! Finance]
Low
Report
Down -39.13% in 4 Weeks, Here's Why You Should You Buy the Dip in Prelude Therapeutics (PRLD) [Yahoo! Finance]
11/8
12:31 pm
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Low
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
11/6
04:22 pm
prld
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
Medium
Report
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]
11/6
04:05 pm
prld
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
Prelude Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
10/28
08:25 am
prld
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
Neutral
Report
Prelude Therapeutics Incorporated (NASDAQ: PRLD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock.
10/24
07:30 am
prld
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
Medium
Report
Prelude Therapeutics Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium
10/9
07:30 am
prld
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium
Medium
Report
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the 36th EORTC-NCI-AACR Symposium